How Much Do Mounjaro and Ozempic Lower A1C?
Mounjaro (tirzepatide) reduces A1C more than Ozempic (semaglutide) in head-to-head trials. In the SURPASS-2 study, patients on 15 mg weekly Mounjaro saw A1C drop by 2.3% from baseline (8.0%), compared to 1.9% for 1 mg weekly Ozempic (8.0% baseline) after 40 weeks.[1] Both started from similar A1C levels around 8%.
What Drives the Difference in Effectiveness?
Mounjaro acts as a dual GLP-1 and GIP receptor agonist, targeting two gut hormones for stronger glucose control and insulin response. Ozempic is a GLP-1 agonist only. This dual mechanism gives Mounjaro an edge: in SURPASS-2, 82-86% of Mounjaro patients hit A1C below 7%, versus 76-79% on Ozempic.[1] Real-world data from studies like TriNetX echo this, with Mounjaro users averaging 2.0-2.5% reductions versus 1.5-2.0% for Ozempic.[2]
Weight Loss Impact on A1C Results
Mounjaro also outperforms on weight, which ties into A1C gains. SURPASS-2 showed 12 kg average loss on high-dose Mounjaro versus 7.7 kg on Ozempic.[1] Greater weight reduction correlates with better glycemic control, especially in obese patients with type 2 diabetes.
Who Sees the Biggest A1C Benefits?
Higher baseline A1C favors Mounjaro. In trials, benefits were consistent across subgroups (age, BMI, duration of diabetes), but patients with A1C over 9% dropped more (up to 2.8% on Mounjaro).[3] Ozempic works well for milder cases but lags in severe hyperglycemia.
Side Effects and Why Some Prefer Ozempic
Both cause nausea, vomiting, and diarrhea, but Mounjaro's rates are similar or slightly higher at max dose (25% vs. 24% for GI issues).[1] Ozempic has longer real-world use and a weekly 2 mg option (approved later), with A1C drops up to 2.1%.[4] No major safety signals differ; choice often hinges on tolerance or insurance.
Cost and Access Comparison
Mounjaro lists at $1,069/month, Ozempic at $936/month without insurance.[5] Coverage varies; Ozempic has more established reimbursement for diabetes. Compounded versions exist but carry risks.
When Might Ozempic Be Better?
If heart disease is a factor, Ozempic has stronger cardiovascular outcome data (SUSTAIN-6 trial: 26% MACE reduction).[6] Mounjaro's CV data (SURPASS-CVOT) is pending full results. For simplicity or lower doses, Ozempic suits needle-phobic patients.
[1]: SURPASS-2 Trial (NEJM, 2021)
[2]: TriNetX Real-World Study (JCEM, 2023)
[3]: SURPASS Program Overview (Diabetes Care, 2022)
[4]: SUSTAIN FORTE (Diabetes Care, 2020)
[5]: Drugs.com Pricing Data
[6]: SUSTAIN-6 Trial (NEJM, 2016)